It’s time to take ownership

It’s time to take ownership
It’s time to take ownership

Blockchain can help you control, protect and share your health data — helping you and others live healthier, longer lives

Exciting advances in precision medicine over the past decade should mean you and your family are now receiving advanced levels of healthcare and disease prevention based on your genetic makeup.

Researchers and health professionals across the world should be enjoying access to a vast resource of genomic sequencing data and health records — helping them discover cures and treatments for every type of disease.

However, the reality is far different.

An ocean of data about your health and the health of others is likely to be spread across many databases. You probably have little ability to view or update this data, let alone control who has access to it.

As for genomic data, only a small percentage of people have had theirs sequenced — largely because there isn’t a secure place to hold and leverage it.

Time to take control

This is a tragedy. You should have the opportunity to own your health and DNA data, and to maintain total control over it. You should have up-to-date information about the diseases you are predisposed to. Every few months, your data dashboard should be updated to inform you of the latest insights scientists have about your DNA.

If you know you’re genetically predisposed to osteoporosis, you should be able to proactively take steps to avoid its onset. If you’re aware there is a high chance of being afflicted by a certain type of cancer, you should be regularly tested to ensure you can catch it early.

Health apps and silos

There are many ongoing initiatives across the globe aiming to facilitate the storage and sharing of genomic data, and thereby enable the progress of precision medicine. Health apps based on genomic and other health data are good examples. But they tend to be competing against each other and creating even more data silos.

Meanwhile, a few large businesses hold the monopoly on most genomic data, and make large profits from selling it to third parties, usually without sharing the earnings with the data donor.

This stifles research and innovation and prevents medicine and healthcare moving forward at the pace it should.

You and your doctors are being denied vital knowledge about your health, and brilliant scientists are being denied access to genomic datasets that could help them gather potentially transformational information that could lead to the eradication of diseases.

Cyber attacks

Not only is your future health being compromised by the current system, but your health data is being left vulnerable too. In the wake of major data breaches like those at Yahoo! and Equifax, it’s hard to trust any organisation with sensitive data stored on cloud databases or local servers.

The release on the internet of your data records could have huge implications on your personal relationships, your future employment, your health insurance and your general wellbeing. Cyber criminals know this, so medical data will increasingly be targeted to leverage money from health organisations and patients themselves.

It’s no wonder few people are largely unwilling to map out their DNA and risk this data being spread across the internet.

A blockchain solution

But blockchain-based technology could be the solution everyone is waiting for.

Its distributed ledger technology removes the vulnerabilities associated with cloud databases. This means it would be safe to store even the most sensitive DNA and healthcare data on the blockchain, without fear of it being stolen or misused in a cyber attack.

A centralized health data hub built on the blockchain could let you maintain full ownership of this data, allowing you to share it with health professionals.

Let’s imagine you’re visiting a specialist doctor for a consultation and tests. She would just need a laptop or mobile device to access your health data in the ecosystem — using a private key (in other words a temporary password) supplied by you. At no time would the data be stored in her own computer or cloud database. And she would only have access to your data while you were under her care.

If you wanted to share the data with a research firm, you could give them access to your data in anonymised form for a certain period, and perhaps receive a payment in exchange.

A new ecosystem

Healthcare and wellness providers such as clinics, pharmaceuticals, research organizations, governments, patient-support groups and insurance companies could join an ecosystem built around this blockchain technology.

They would no longer have to compete with each other to gather data. It would be there for them all to use — for example, to boost clinical trials or facilitate drug research and development. This data could be easily sharable and interoperable across technological, geographic, jurisdictional, and professional boundaries.

Sharing data

Such a system could offer patients access to applications that leverage their data and enhance their wellbeing and health — for example, nutritional and fitness advice, treatment plans, genealogy, disease predisposition, and lifestyle management.

Looking into the future, as more personalized biological information becomes available, services could be offered that are based not only on genomic data, but also other health, biological, and environmental information, facilitating new insights into disease processes.

This is an exciting time in healthcare. Soon, you’ll have the power to leverage your DNA and health data to live a longer, healthier life, while helping billions of others on the planet.

All the technologies are in place. The world just needs a suitable health data platform.

About the Author

Dr Axel Schumacher who has over 20 years’ experience in the field of genetics; and is the Chief Scientific Officer of blockchain-enabled genomic data-hub startup Shivom. Shivom’s platform aims to be the largest genomic & healthcare data-hub on the planet, allowing the world’s population to have their genome sequenced and securely stored with the help of blockchain technology.

September Sickle Cell Awareness Campaign — Plus more updates about our Diabetes work in India

September Sickle Cell Awareness Campaign India
September Sickle Cell Awareness Campaign India

Following the announcement of our partnership with eMQT, Shivom asks the community to take a moment to reflect on the devastating genetic disorder Sickle Cell Disease (SCD)

SCD is a blood disease and particularly common in people with an African or Caribbean family background. Patients with SCD produce irregular shaped red blood cells that can cause complications because they don’t live as long as healthy blood cells and can’t carry enough oxygen around the body. Due to their shape, these blood cells can get stuck inside smaller blood vessels. This keeps blood from flowing and can cause pain and severe damage to parts of the body, ultimately leading to a reduced life expectancy.

We are inviting patients, physicians, and researchers to share their experiences with SCD on our social media channels.

Follow us, tweet at us @ProjectShivom, and use the hashtag #SickleCellAwareness OR you can send us your story to info@shivom.io

Read more about our work with SCD and our partnership with eMQT here

Moving Forward with Diabetes Pilot in India

Moving Forward with Diabetes Pilot in India

Towards the end of September our CEO, Henry Ines, and our Co-Founder and CSO, Dr. Axel Schumacher will again head to India to begin our Type II diabetes (T2D) pilot study in the state of Andhra Pradesh, located in the south-eastern part of the subcontinent. Together with our Indian partners, including a diagnostics clinic and local doctors, we will initiate the collection of DNA samples from diabetes patients and matched control subjects. Among others, the work will also involve setting up recruitment, sample logistics, educational programs, and standard operating procedures for the pilot and further projects. identification of biomarkers for accurate classification of patient subgroupsOur pilot program serves to bring precision medicine studies to the next era. The study will not only aim at finding genotypes that are specific to Indian sub populations but help diagnose and treat the disease. Collected data will help to further our blockchain platform, provide a proof of concept of assigning digital identities for the local population, and provide data ownership to study participants. By using state-of-the-art AI algorithms, Shivom and our partners will work towards the identification of biomarkers for accurate classification of patient subgroups and diabetes management apps within our platform.

 

What’s New with Our Platform?

We are thrilled by the high-interest shown by our community to test one of our first modules. Please stay tuned for more information regarding the release date and details for logging into the test module.

We look forward to providing the community with more updates next month and hearing your SCD stories.

As always, we thank you for your continued support and dedication.

Shivom Team

Exciting Changes within SHIVOM’s Management Team!

Exciting Changes within SHIVOM’s Management Team
Exciting Changes within SHIVOM’s Management Team

Here at OMIX Ventures Pvt Ltd. Project SHIVOM (Token Ticker: OMX), now post-ICO and focused on execution and growth, the leadership team has decided to make some significant management changes to ensure efficient execution and platform roll out.

We’re thrilled to announce that Henry Ines has been named as Chief Executive Officer of the global blockchain-based genomics and precision medicine services company.

Henry has deep experience and knowledge of strategic development, corporate finance, startup scaling and execution based on decades of professional experience to include years as a VC, while working in Silicon Valley and Asia as a partner at Draper Dragon Fund, DFJ Dragon Fund and DragonVenture and focusing on early stage investments in frontier technologies to include FinTech & blockchain, artificial intelligence and VR/AR. Henry continues to serve on the advisory board of multiple Blockchain and Silicon Valley tech startups and serves as a mentor to leading incubators and accelerators. Henry is also a lecturer at the Nanyang Technopreneurship Center (NTC), Nanyang Technological University (NTU) and is a Senior Member of the World Education Blockchain Association (WEBA) in Singapore. He began his career at McNeil Consumer Products Company, a subsidiary of Johnson & Johnson, and as a management consultant to Fortune 100 companies while working at Price Waterhouse LLP. Henry holds a BS in Finance from Pennsylvania State University in University Park, PA and an MBA from Duke University Fuqua School of Business in Durham, NC.

“As we enter the Post-ICO phase, I am thrilled to lead the team at SHIVOM, focusing on tackling the many problems associated with the global healthcare system through genomics. The current healthcare system continues to be inefficient and face considerable challenges. Patients’ data continues to not be secure as is evident with the recent disclosures of data breaches. Additionally, many of the prevailing genetics companies and healthcare intermediaries continue to advance business models and practices that are not necessarily consistent with and in the best interests of donors or patients. We are looking forward to being able to empower individuals by providing significant insights into their genomes and health, tools for better managing and determining who has access to personal healthcare data, and enabling individuals to better manage their health and wellness through SHIVOM’s secure blockchain-based technology platform and healthcare ecosystem.”

Dr. Axel Schumacher, company co-founder who has been CEO up to now will continue as Chief Scientific Officer, leveraging his extensive research background and expertise in genomics and precision medicine. Additionally, Dr. Natalie Pankova moves into the role of Chief Operating Officer, and will lead operations out of our London office, leveraging her background in startup operations, business development and R&D, as well as her deep involvement in the global healthcare blockchain community. We believe these roles reflect the most direct path to success for our company, our supporters, and our vision.

SHIVOM cannot wait to build the world’s largest genomics datahub to help support clinical trials, advance research and development and drug discovery process globally, and ultimately work to democratize genomics for all. It is our mission to not only maintain a secure and safe platform for our users and web-market players, but also address the genomic-based complex and rare diseases such as diabetes utilizing advanced technologies such as blockchain and artificial intelligence.

We have a very special team that is dedicated to SHIVOM’s mission and working hard to execute in accordance with the company’s roadmap and growth strategy. As a startup, we must be nimble, iterate as needed and quickly respond to dynamic and evolving conditions. We are confident about our new changes, and keen to work together in new capacities to more effectively execute on our vision and take the company to new heights.

Thank you for your continued support as we enter this new wave of development, and stay tuned into our media outlets for more exciting news coming soon!

Shivom Management Team

Shivom Partners With SingularityNET For Strengthening Genomics Medical Research and Advanced…

As a step forward towards building the world’s most extensive database of DNA records, we have partnered with SingularityNETso, the pioneers of innovations in AI and deep learning. Popular for being one of the contributors to the development of the world’s first Humanoid ‘Sophia’, SingularityNET’s AI will strengthen our toolset for providing personalized medical analytics by integrating with Shivom’s decentralized network capability.

SingularityNET’s decentralized AI network provides an open market for anyone to develop, share and monetize AI services and algorithms. This is a lucrative alliance for communities in both entities to go full throttle and unlatch optimal benefits.

Shivom Partners With SingularityNET For Strengthening Genomics Medical Research and Advanced

Going Ahead — Strengthening Shivom For The Long Term

Post successful integration of the two networks, AI agents on the SingularityNET’s decentralized platform can request biological datasets from Shivom, to execute certain analytical tasks. Similarly, a Shivom customer can seek AI analytics to be performed on the genomics data uploaded.

Such synergized networks will help boost medical professionals, researchers and the customers needs with a more accurate and more hassle-free understanding of one’s health analysis bypassing impediments in data flow necessary for this type of analysis to take place via 3rd party services.

The cross-disciplinary data sharing amidst the two networks will be driven by automated conversion between the Shivom Tokens and SingularityNET’s AGI Tokens. Followed by deep encryption of datasets in transaction coupled with cross-network reputation management, the fundamental principle of the Blockchain towards data privacy is assured.

” Shivom Co-Founder and CEO, Dr. Axel Schumacher, elaborated on the partnership and said “We are excited to work with SingularityNET. AI approaches are well suited to model the complex dependencies in the regulatory landscape of our genome and can help to predict an individual’s probability of developing certain diseases. Such information should be made actionable. As such, we are confident that AI will play a central role in our platform for achieving greater depth in the interpretation of genetic information such as how an individual’s genes may impact their lifestyle decisions or help their healthcare providers to design of potential therapies.”

SingularityNET CEO, Dr. Ben Goertzel pitched in saying, “ “We are enthused to have the opportunity to support Shivom’s vision of next-era genomic research. The Shivom vision synergizes beautifully with the SingularityNET vision; the integration of Shivom’s technology, tools, and data with our SingularityNET mind-network will add more scope and intelligence into the field of personalized medical analytics.I. Together, we can achieve great things for medical science by utilizing high-quality datasets, SingularityNET’s algorithms and customer base for biomedical analytics services, and Shivom’s genomics-focused software.”

What’s Ahead?

In our mission to unlock the data stored in billions of genetic codes across the globe, this alliance is a breakthrough move. As partners, we really look forward to redefining medical research as we usher in a new era of healthcare and maximize the capabilities of Shivom’s genetic data storage and analysis platform.